Updated Oct. 20, 2021 9:24 americium ET / Original Oct. 20, 2021 6:09 americium ET
- Order Reprints
- Print Article
Shares of U.S. biotech Novavax were falling much than 23% successful premarket trading Wednesday connected a study the institution was inactive struggling to amusement that it tin manufacture its Covid-19 jab with prime standards that conscionable U.S. regulator’s requirements.
Maryland-based Novavax (ticker: NVAX), which has ne'er produced a vaccine before, has submitted its vaccine for support to U.S. and European Union regulators aft palmy signifier 3 trials showed it had a 93% efficacy against predominantly circulating variants of the virus.